Immunate Stim Plus

Human Coagulation Factor VIII and Human von Willebrand Factor, the active ingredient in Immunate Stim Plus, is a coagulation factor replacement therapy presented as a sterile solution for intravenous use. It replaces deficient clotting proteins to treat patients with Hemophilia A and von Willebrand disease.

GNH USA supplies Immunate Stim Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Immunate Stim Plus is used in the management of inherited bleeding disorders that involve deficiency of factor VIII or von Willebrand factor. - Hemophilia A: provides factor VIII to achieve hemostasis and reduce bleeding episodes. - von Willebrand disease: supplies von Willebrand factor to improve platelet adhesion and stabilize clot formation. - Surgical prophylaxis in hemophilia or von Willebrand disease: maintains clotting factor levels during invasive procedures to prevent peri‑operative bleeding.

Common Side Effects: - Infusion‑related reactions such as chills, fever, or flushing. - Headache or mild dizziness. - Nausea or transient abdominal discomfort. - Transient hypertension during infusion.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Development of inhibitory antibodies against factor VIII or von Willebrand factor. - Thromboembolic events including deep vein thrombosis. - Severe hemolysis or disseminated intravascular coagulation.

Immunate Stim Plus should be used under specialist supervision with attention to the following precautions. - Inhibitor monitoring: assess for development of neutralizing antibodies. - Bleeding history: evaluate prior bleeding episodes and factor levels. - Specialist oversight: administer only by trained healthcare professionals. - Hypersensitivity: avoid in patients with known allergy to human plasma proteins. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunate Stim Plus may interact with other agents that affect coagulation. Major Interactions (Avoid): - Concurrent use of other clotting factor concentrates may lead to excessive clotting. - Co‑administration with activated prothrombin complex concentrates can increase thrombosis risk. Moderate Interactions (Monitor Closely): - Use with antifibrinolytic agents (e.g., tranexamic acid) may enhance clot stability; monitor for thrombotic signs. - Immunosuppressive therapy may alter inhibitor development; observe antibody titres. - Certain antibiotics (e.g., rifampin) may affect plasma protein levels; check factor activity.